325 related articles for article (PubMed ID: 31674023)
1. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
2. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
3. A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway.
Zhang H; Liu X; Wu F; Qin F; Feng P; Xu T; Li X; Yang L
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196894
[TBL] [Abstract][Full Text] [Related]
4. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387
[TBL] [Abstract][Full Text] [Related]
5. Formulation and evaluation of anticancer and antiangiogenesis efficiency of PLA-PEG nanoparticles loaded with galbanic acid in C26 colon carcinoma, in vitro and in vivo.
Afsharzadeh M; Abnous K; Yazdian-Robati R; Ataranzadeh A; Ramezani M; Hashemi M
J Cell Physiol; 2019 May; 234(5):6099-6107. PubMed ID: 30378118
[TBL] [Abstract][Full Text] [Related]
6. Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.
Pan M; Li W; Yang J; Li Z; Zhao J; Xiao Y; Xing Y; Zhang X; Ju W
Medicine (Baltimore); 2017 Jul; 96(30):e7405. PubMed ID: 28746182
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.
Meher N; Ashley GW; Bidkar AP; Dhrona S; Fong C; Fontaine SD; Beckford Vera DR; Wilson DM; Seo Y; Santi DV; VanBrocklin HF; Flavell RR
ACS Appl Mater Interfaces; 2022 Nov; 14(45):50569-50582. PubMed ID: 36318757
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR
ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058
[TBL] [Abstract][Full Text] [Related]
9. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
10.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.
Chen Y; Xu Z; Lu T; Luo J; Xue H
Drug Deliv; 2022 Dec; 29(1):2705-2712. PubMed ID: 35980107
[TBL] [Abstract][Full Text] [Related]
12. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.
Xu X; Wu J; Liu Y; Saw PE; Tao W; Yu M; Zope H; Si M; Victorious A; Rasmussen J; Ayyash D; Farokhzad OC; Shi J
ACS Nano; 2017 Mar; 11(3):2618-2627. PubMed ID: 28240870
[TBL] [Abstract][Full Text] [Related]
14. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
15. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and
Cordonnier A; Boyer D; Besse S; Valleix R; Mahiou R; Quintana M; Briat A; Benbakkar M; Penault-Llorca F; Maisonial-Besset A; Maunit B; Tarrit S; Vivier M; Witkowski T; Mazuel L; Degoul F; Miot-Noirault E; Chezal JM
J Mater Chem B; 2021 Sep; 9(36):7423-7434. PubMed ID: 34373887
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R
Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166
[TBL] [Abstract][Full Text] [Related]
18. Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy.
Lee S; Lee Y; Kim H; Lee DY; Jon S
Biomacromolecules; 2018 Jun; 19(6):2270-2277. PubMed ID: 29712433
[TBL] [Abstract][Full Text] [Related]
19. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
20. Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release.
Li Y; Wu H; Yang X; Jia M; Li Y; Huang Y; Lin J; Wu S; Hou Z
Mol Pharm; 2014 Aug; 11(8):2915-27. PubMed ID: 24984984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
